# US 7,410,954 B2 · Adenovirus serotype 30 (Ad30) > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 7,410,954 B2 - Document ID: US7410954B2 - Status: Granted - Kind: B2 - Application number: 10/621,006 - Filed: 2003-07-15 - Published: 2004-02-26 - Granted: 2008-08-12 - Earliest claimed: 2001-01-09 - Assignees: University of Iowa Research Foundation - Inventors: Beverly L. Davidson; Lane K. Law - Web page: https://patentgrep.com/patent/US7410954B2 ## CPC - C07K 14/005: from viruses - C12N 15/86: Viral vectors - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy - C07K 2319/00: Fusion polypeptide - C12N 2710/10322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - C12N 2710/10344: Chimeric viral vector comprising heterologous viral elements for production of another viral vector - C12N 2810/6018: Adenoviridae - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The present invention provides an adenovirus serotype 30 (Ad30) fiber amino acid sequence. The present invention also provides polynucleotides and expression vectors encoding an Ad30 fiber and viral particles and cells containing such expression vectors. The present invention further provides methods of treating genetic diseases or cancers in a mammal using the polynucleotides, polypeptides, expression vectors, viral particles and cells of the present invention. ## Claims ### Claim 1 A method of transducing a cell lacking coxsackievirus and adenovirus receptor (CAR) comprising contacting the cell with an expression vector comprising an Ad backbone nucleic acid sequence and polynucleotide encoding a chimeric adenovirus (Ad) fiber polypeptide comprising at least one of the following: a tail region, a shaft region and a knob region, wherein the polynucleotide encoding a chimeric Ad fiber polypeptide encodes SEQ ID NO:1, encodes amino acids 46-188 of SEQ ID NO:1, encodes amino acids 189-371 of SEQ ID NO:1, or wherein the polynucleotide comprises SEQ ID NO:12, comprises nucleotides 1-564 of SEQ ID NO:12, comprises nucleotides 1-135 of SEQ ID NO:12, or comprises nucleotides 136-564 of SEQ ID NO:12. ### Claim 2 (depends on 1) The method of claim 1, wherein the polynucleotide encoding a chimeric Ad fiber polypeptide encodes SEQ ID NO:1. ### Claim 3 (depends on 1) The method of claim 1, wherein the shaft region comprises amino acids 46-188 of SEQ ID NO:1. ### Claim 4 (depends on 1) The method of claim 1, wherein the knob region comprises amino acids 189-371 of SEQ ID NO:1. ### Claim 5 (depends on 1) The method of claim 1, wherein the polynucleotide encoding a chimeric Ad fiber polypeptide comprises SEQ ID NO:12. ### Claim 6 (depends on 5) The method of claim 5, wherein the polynucleotide comprises nucleotides 1-564 of SEQ ID NO:12. ### Claim 7 (depends on 1) The method of claim 1, wherein the polynucleotide encoding a chimeric Ad fiber polypeptide comprises nucleotides 1-135 of SEQ ID NO:12. ### Claim 8 (depends on 1) The method of claim 1, wherein the polynucleotide comprises nucleotides 136-564 of SEQ ID NO:12. ### Claim 9 (depends on 1) The method of claim 1, wherein the tail region is an Ad5 tail region, the shaft region is an Ad30shaft region comprising amino acids 46-188 of SEQ ID NO:1, and the knob region is an Ad30knob region. ### Claim 10 (depends on 9) The method of claim 9, wherein the polynucleotide encoding the shaft region comprises nucleotides 136-564 of SEQ ID NO:12. ### Claim 11 (depends on 1) The method of claim 1, wherein the expression vector further comprises a nucleotide sequence encoding a therapeutic agent. ### Claim 12 (depends on 1) The method of claim 1, wherein the polynucleotide encoding a chimeric Ad fiber polypeptide is operably linked to a polynucleotide encoding an amino acid sequence for a therapeutic agent. ### Claim 13 (depends on 1) The method of claim 1, wherein the cell is a neuronal or epithelial cell. ### Claim 14 (depends on 13) The method of claim 13, wherein the cell is a human umbilical vein epithelial cell (HUVEC). ### Claim 15 (depends on 1) The method of claim 1, wherein the cell is a tumor cell. ### Claim 16 (depends on 15) The method of claim 15, wherein the tumor cell is from prostate, brain, breast, lung, spleen, kidney, heart, or liver. ### Claim 17 (depends on 1) The method of claim 1, wherein the cell is a neuroprogenitor or stem cell.